Drug - International Biopharmaceutical Industry

Current Edition

Current Features

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Subsection - Oncology

Essential DMPK Strategies for IND Success

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

news

Daiichi acquires another ADC drug through Glycotope licensing deal

Daiichi Sankyo is bringing a seventh antibody-drug conjugate, or ADC, into its pipeline through a licensing agreement with German biotech Glycotope. Specific fin...

31 July 2018 news acquires | ADC

Continue Reading →

news

Allergan’s eye drug stacks up against Lucentis, but wider market still iffy

Allergan on Thursday touted data from two late-stage trials that showed a drug it in-licensed from a Swiss biotech proved non-inferior to Lucentis in the treatment...

20 July 2018 news Allergan | Drug

Continue Reading →

news

Merck inks deal with China’s Xian Janssen for type 2 diabetes drug

China has more than 114 million people living with diabetes, the largest number of any country in the world Global drug giant, Merck signed an agreement with Chi...

13 July 2018 news 2 | China's Xian

Continue Reading →

news

Drug, device companies gave docs, hospitals $8.4B in 2017

Doctors and teaching hospitals received $8.4 billion from drug and device companies in 2017, according to the latest Centers for Medicare and Medicaid Services Open...

6 July 2018 news $8.4B | 2017

Continue Reading →

news

Half of orphan drug sales to come from cancer, Evaluate finds

Oncology already sits as the top-selling therapeutic area on the orphan drug market, but a new report predicts it to account for even more — half, in fact — of sa...

1 June 2018 news cancer | Drug

Continue Reading →

news

Amgen, Novartis’ closely watched migraine drug approved

Amgen and Novartis on Thursday secured Food and Drug Administration approval for Aimovig, the first regulatory thumbs up for a new class of migraine treatments ca...

21 May 2018 news Amgen | approved

Continue Reading →

news

United Therapeutics nabs competing PAH drug with $216M SteadyMed buy

Brief: United Therapeutics announced Monday morning that it will acquire competitor SteadyMed for $4.46 per share in cash upfront and another $2.63 per share in c...

1 May 2018 news 216 | Drug

Continue Reading →

news

AACR 2018: GamaMabs Pharma to present new data on expression of Anti-Müllerian Hormone type II Receptor in non-gynecological cancers and on first ADC candidate targeting AMHRII

AMHRII expression and Antibody-Drug Conjugate preclinical data suggest potential broader applications for anti-AMHRII-based therapy GamaMabs Pharma, a biotechnolog...

12 April 2018 news AACR | AMHRII

Continue Reading →